R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by ...
The official figures allow schools to be sorted by a variety of metrics, although this year, the default one commonly used to rank them has changed. School performance is being measured by their ...
KEY POINTS Drilling from the end of the Ming mine exploration drive has extended the known mineralisation by 430m beyond ...